Daily Stock List
Zivo Bioscience, Inc. (ZIVO)
RedChip reported earlier on Zivo Bioscience, Inc. (ZIVO), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.
Zivo Bioscience, Inc.’s dedication is to the study, development, and commercialization of naturally derived compounds and bioactive molecules created by algal and bacterial hosts. The Company has partnered with the Arizona Center for Algae Technology and Innovation (AzCATI) for its research and development (R&D) development programs. Zivo Bioscience is re-inventing its Company as a licensor of internally developed intellectual property (IP) that includes its proprietary algae cultures, in addition to IP secured via strategic acquisitions.
The Company formerly went by the name Health Enhancement Products, Inc. It changed its corporate name to Zivo Bioscience, Inc. in November of 2014. Zivo Bioscience has its headquarters in Keego Harbor, Michigan. The Company’s commitment is to the ideal of promoting health through employing naturally occurring bioactive agents. These active ingredients are produced and processed to obtain the highest possible efficacy.
To maximize the value and earning power of licenses, Zivo Bioscience engages in continuing R&D to provide its licensees with the scientific and technical support needed to move into production and distribution. The Company works to totally harness the beneficial effects of its natural bioactive agents and make them affordable and readily available in a useful and convenient form.
Zivo Bioscience’s core IP consists of the algae culture itself, the patented process of producing that culture, as well as the bioactive compounds or molecules that can be extracted. Its core IP additionally consists of the application of that culture or extract in supporting health maintenance and longevity.
Zivo Bioscience announced this past January that preliminary results and analyses of its pilot bovine mastitis study were accepted and reviewed by Zivo’s science team. Dairy Experts, Inc., based in Northern California, conducted the study on behalf of Zivo Bioscience over the course of spring/fall 2014. Zivo is waiting on a final report from the principal investigator leading the study team in California.
Zivo Bioscience, Inc. (ZIVO), closed Friday's trading session at $0.07, up 0.43%, on 109,977 volume with 10 trades. The average volume for the last 60 days is 89,918 and the stock's 52-week low/high is $0.05/$0.2299.
OXIS International, Inc. (OXIS)
TopPennyStockMovers, Gryphon Digest, and PennyStocks24 reported earlier on OXIS International, Inc. (OXIS), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
OXIS International, Inc. is a biotechnology company centering on cannabinoid therapy development and commercialization. The Tampa, Florida-based Company develops and commercializes unique drugs of therapeutic molecules including cannabinoids that are focusing on many cancer indications. OXIS International addresses the clinical shortcomings of existing commercial products in related fields. The Company’s wholly-owned subsidiary is Oxis Biotech, Inc.
OXIS International has developed relationships with some of the world's top cannabinoid researchers and institutions to advance its technologies. The Company’s emphasis is to produce a platform of synthesized cannabinoid agents, which target the treatment of cancer cells in multiple areas. It will do so using the powerful compounds found in cannabinoid-producing plants.
OXIS’ wholly-owned subsidiary, Oxis Biotech, has executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma. Oxis Biotech also initiated a consulting agreement with University of Pittsburgh's Professor, Dr. Xiang-Qun (Sean) Xie. The license agreement provides Oxis Biotech an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma. Dr. Xie joined Oxis Biotech as a consultant and member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech.
OXIS International announced this past January that Dr. James J. Mulé joined the Scientific Advisory Board for the Company’s wholly-owned subsidiary, Oxis Biotech. Dr. Mulé, Ph.D. presently serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center.
OXIS International has its new worldwide exclusive Patent Licensing of "P62 Chemical Agents and Multiple Myeloma Therapeutics", with Dr. Xiang-Qun (Sean) Xie. Dr. Xie, MD, PhD, EMBA is one of the world's leading cannabinoid research scientists. With the inclusion of its P62 Multiple Myeloma Therapeutics platform, OXIX is positioned to be a significant player in the large and expanding market for Myeloma Therapeutic drug therapies.
OXIS International’s focus for 2015 is to continue to make major progress with Oxis Biotech, Inc. through adding additional high value patents and assets to its portfolio over the very near future. At the beginning of April, subsidiary Oxis Biotech discussed during its March 31, 2015 conference call with shareholders, analysts, and other interested parties certain aspects of its immunotherapeutic development strategy. Mr. Anthony J. Cataldo, Chairman and CEO, stated that Oxis Biotech is concentrating on developing immunotherapies for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions, which are significant unmet medical needs.
OXIS International, Inc. (OXIS), closed Friday's trading session at $0.03068, up 0.92%, on 810,652 volume with 74 trades. The average volume for the last 60 days is 4,250,562 and the stock's 52-week low/high is $0.0032/$0.07.
Millennium HealthCare, Inc. (MHCC)
PennyStocks24, Stock Onion, Planet Penny Stocks, Buzz Stocks, PennyStockProphet, SecretStockPromo, Penny Pick Finders, TheMicrocapNews, and SmallCapVoice reported on Millennium HealthCare, Inc. (MHCC), and we report on the Company also, here at the QualityStocks Daily Newsletter.
Millennium HealthCare, Inc., through its wholly-owned operating subsidiaries, provides primary care physician practices, physician groups, and healthcare facilities of all sizes with front-line medical devices focused mainly on preventive care via early detection. The Company operates in three segments: Coding, Device, and Vascular. It purchases, supplies, and distributes innovative medical devices and equipment with an emphasis on prevention and early detection. Millennium Medical Devices (MMD) is a wholly-owned subsidiary of Millennium Healthcare. Millennium HealthCare is based in Garden City, New York.
The Company also provides physician practice development, support, and administration services for physician facilities and practices primarily for vascular disorders. This includes peripheral arterial disease of the lower extremities. In addition, Millennium HealthCare offers support and services specializing in medical procedure billing and collections, medical procedure coding, call and message management, and emergency dispatch.
The design of Millennium HealthCare VasoScan™ is to analyze Autonomic Nervous System (ANS) function, Stress, and Peripheral Blood Circulation. It provides objective data to assist in assessing disorders. These include depression, anxiety, sleep disorder, poor concentration, mental/physical stress degree, chronic fatigue, and also blood circulation.
Millenium’s subsidiary, MMD, signed an exclusive agreement with CDx Diagnostics for distribution of DermCDx™, a brush biopsy test kit used to confirm suspected basal cell carcinoma (BCC). DermCDx is a minimally invasive test. It combines a patented brush biopsy sampling instrument with computer-assisted three dimensional laboratory analysis.
Millennium HealthCare, through MMD, has an exclusive agreement with CDx Diagnostics to distribute its OralCDx brush biopsy test kit. OralCDx is a non-invasive test used to test dysplasia (the small white and red tissue spots commonly found in the mouth) to rule out precancerous change. The test has previously been available to dentists nationwide. Through this exclusive collaboration, Primary Care Physicians will be able to administer this test to their patients.
Q3 of 2014 was the first full quarter where Millennium HealthCare placed its exclusive OralCDx® and VasoScan™ diagnostic devices with its existing network of primary care physician groups. For the first half of this year, Company Management plans to continue its efforts on growing and enhancing the training, certification, and customer service for its existing products by way of its established channels and networks to further build on a core foundation for its exclusive devices. Management also plans to introduce the Company’s products into new sales partnerships and channels throughout the second half of 2015. Additionally, Millennium HealthCare’s intention is to introduce new products to its growing customer channels and networks.
Millennium HealthCare, Inc. (MHCC), closed Friday's trading session at $0.0425, up 41.67%, on 1,143,927 volume with 52 trades. The average volume for the last 60 days is 875,854 and the stock's 52-week low/high is $0.0251/$0.85.
Epoxy, Inc. (EPXY)
TopPennyStockMovers reported earlier on Epoxy, Inc. (EPXY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Epoxy, Inc. is the developer of the Epoxy app, which is an application or "app" for iPhone iOS and Android operating systems. Epoxy is an innovative smart phone application. The design of it is to conveniently connect business owners and consumers to reduce marketing frustrations. Epoxy is a fully integrated mobile application business. The OTCQB-listed Company is headquartered in Las Vegas, Nevada.
The commitment of Epoxy designers is to providing a superior and user-friendly product for business owners to reward loyal customers. The Epoxy mobile app gives loyal customers the ease of keeping track of rewards and punch cards all in one place. This is while also giving opportunities to review and share businesses with friends.
Sequentially, the Company provides businesses the ability to reward, share offers, and deliver information regarding special events with its customers, and offer card-less gift cards directly via smart phones.
Epoxy has successfully expanded to New York, New York with the addition of Empowered Hypnosis Centers. Furthermore, Epoxy has started beta testing in Europe. The Company has started testing in The UAE (United Arab Emirates) and Germany due to repeated requests and overwhelming interest from the regions.
In addition, Epoxy has been targeting professional business services to add to its developing portfolio of clients. This includes Optometry, Health and Wellness, and Technology firms.
Epoxy announced in April that it successfully completed its Phase one expansion into Germany. It has started working on Phase two. Phase one consists of rendering the best types of markets and deploying the Epoxy App in English. Phase Two consists of translating the Application to German and offering the German marketplace incentives for signing up.
Epoxy has created an entirely different admin panel. The new admin panel design is cleaner and more intuitive. It provides business owners total control over the implementation of the Epoxy App. This control includes access to high-end analytics that report metrics. Business owners will also be able to easily update page content and send messages to the entire network, or single out and reward individual customers.
Epoxy, Inc. (EPXY), closed Friday's trading session at $0.0356, up 1.42%, on 265,459 volume with 13 trades. The average volume for the last 60 days is 535,202 and the stock's 52-week low/high is $0.0069/$0.18.
U.S. Precious Metals, Inc. (USPR)
Proactivecrg, PennyStocks24, Stocks That Move, and Streetwise Reports reported earlier on U.S. Precious Metals, Inc. (USPR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Marlboro, New Jersey-based U.S. Precious Metals, Inc. engages in the acquisition, exploration, and development of mineral properties. Its mission is to discover, acquire, define, and develop gold deposits and other valuable metals. The Company’s development projects are primarily in Mexico, and also throughout the Americas. U.S. Precious Metals is centering on gold, silver, and copper chiefly situated in the State of Michoacán, Mexico.
The Company owns exploration and exploitation concessions to approximately 37,000 contiguous acres of mineral rights. The 17,000-hectare Solidaridad mining leases are held by U.S. Precious Metals of Mexico, a wholly-owned subsidiary of the Company. The Solidaridad properties consist of eight concessions granted by the Mexican government for a 50-year period.
On May 22, 2013, U.S. Precious Metals entered into an agreement with Mesa Acquisitions Group, LLC, in association with Alba Petroleos, to further explore and develop U.S. Precious Metals’ Mexican concessions. Mesa Acquisitions/Alba Petroleos committed to spend up to roughly $50 million to explore and develop pre-determined portions of two of U.S. Precious Metals’ Mexican concessions known as Solidaridad 1 & Solidaridad 2.
In addition, it will construct the necessary plant and/or bring in the needed equipment to process the head ore. In addition, U.S. Precious Metals acquired Resource Technology Corp. Consequently, it has incorporated the newest technological advancements in ore refining through adopting Thermal processing.
This past March, U.S. Precious Metals announced the hiring of ACT HOLDINGS, LLC, (ACT) to act as operator for the Company's 2015 core drilling program on its mining concessions in Michoacán, Mexico. The program initially consists of 5,000 meters, which target areas near drill holes from previous drilling campaigns to expand and define known mineralized zones at depth.
Additionally, specific anomalies identified by the Company's satellite imaging and ground geophysics in earlier unexplored areas are additional targets of this drilling campaign. In these areas, the Company's objective is to confirm with core drilling several anomalies identified by previous imaging and geophysical data.
U.S. Precious Metals, Inc. (USPR), closed Friday's trading session at $0.1275, up 7.91%, on 532,490 volume with 41 trades. The average volume for the last 60 days is 157,889 and the stock's 52-week low/high is $0.11/$0.325.
Arch Therapeutics, Inc. (ARTH)
Wall Street Resources, RedChip, and PennyStocks24 reported earlier on Arch Therapeutics, Inc. (ARTH), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Arch Therapeutics, Inc. is a medical device company that is developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Its goal is to develop and commercialize products based on its pioneering technology platform. This platform makes surgery and interventional care faster and safer for patients. Arch Therapeutics is headquartered in Wellesley, Massachusetts.
The underlying technology, exclusively licensed from a leading university, supports an inventive platform of smart materials that fulfill the criteria as a solution for a specialized field the Company calls, “stasis and barrier applications.” Arch Therapeutics’ flagship development stage product candidate is known as AC5™ (AC5 Surgical Hemostatic Device™). This is a synthetic peptide consisting of naturally occurring amino acids.
AC5™ is undergoing design to smoothly achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures. Its solution smartly controls the movement of fluids and substances. AC5™ stops bleeding quickly. AC5™ conforms to irregular wound geometry and assists in maintaining a clear field of vision directly into the wound area.
AC5™, when squirted or sprayed onto a wound, rapidly intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances (including blood and other bodily fluids) regardless of type of surgery or, based on early data, clotting ability, and healing occurs normally.
Arch Therapeutics indicates that in preclinical tests, AC5™ has been simple, effective, and versatile. To date, biocompatibility has been excellent and healing of tissue treated with the device has been normal.
Arch Therapeutics announced recently that an independent third party obtained favorable data from an animal study, which compared the hemostatic activity of AC5 with a commercially available branded hemostat consisting of a flowable gelatin combined with thrombin. In the study, full thickness penetrating wounds were surgically created in rat livers, which are highly vascularized parenchymal organs, and then either AC5™ or gelatin-thrombin hemostat was applied to stop the bleeding.
The time to hemostasis (TTH) - the time required to stop bleeding - was measured. The average TTH after application of AC5 was considerably less than 30 seconds. The average TTH after application of the gelatin-thrombin hemostat was more than 200 percent longer.
Arch Therapeutics, Inc. (ARTH), closed Friday's trading session at $0.23, up 13.81%, on 1,847,841 volume with 332 trades. The average volume for the last 60 days is 152,477 and the stock's 52-week low/high is $0.15/$0.28.
Global Digital Solutions, Inc. (GDSI)
PennyStocks24 reported previously on Global Digital Solutions, Inc. (GDSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Global Digital Solutions, Inc. is positioning itself as a leader in providing cyber arms manufacturing, complementary security and technology solutions, and knowledge-based, cyber-related, culturally attuned social consulting in unsettled areas. The Company’s emphasis is on diverse military-related products and services.
Global Digital Solutions’ aim is to become a foremost provider of defense technology-based solutions and systems to commercial customers, the U.S. military and foreign allies, and U.S. government civil agencies and friendly counterparts. Global Digital Solutions has its corporate office in West Palm Beach, Florida.
The Company’s military-related products and services, which it is working to bring online, include an innovative group of technology-enhanced services. These offer personalized, digital small arms safety and security solutions in commercial and military-related markets. Global Digital Solutions announced in June 2014 the acquisition of North American Custom Specialty Vehicles, LLC (NACSV).
NACSV is a leading builder of mobile command/communications and specialty vehicles for emergency management, first responders, national security and law enforcement operations. On June 16, 2014, Global Digital Solutions’ wholly-owned subsidiary, GDSI Acquisition Corp., entered into an Equity Purchase Agreement with the members of NACSV to acquire its interests in NACSV.
Organizations widely use NACSV surveillance vehicles for a variety of purposes. These include live surveillance, providing back-to-base video and data links to support command and control decision making, and also the provision of intelligence in hostile situations where normal vehicle support is not possible.
This past December, Global Digital Solutions announced that, effective December 3, 2014, Jennifer Carroll, former Lt. Governor of Florida, assumed the duties of President and Chief Executive Officer (CEO) of the Company’s wholly-owned subsidiary, North American Custom Specialty Vehicles (NACSV). Ms. Carroll has served as a Global Digital Solutions Senior Advisor since April of 2013.
The features of Global Digital Solutions’ growth plan include transformative, IP-rich cyber technologies, fortifying its brand leadership strategy via partnerships and alliances, a worldwide shareholder base, and a proven strategic vision.
Global Digital Solutions, Inc. (GDSI), closed Friday's trading session at $0.115, up 4.55%, on 75,700 volume with 11 trades. The average volume for the last 60 days is 177,196 and the stock's 52-week low/high is $0.03/$0.70.
Inventergy Global, Inc. (INVT)
The QualityStocks Daily Newsletter would like to spotlight Inventergy Global, Inc. (INVT). Today, Inventergy Global, Inc. closed trading at $0.35, up 12.90%, on 362,875 volume with 544 trades. The stock’s average daily volume over the past 60 days is 383,006, and its 52-week low/high is $0.305/$9.90.
Inventergy Global, Inc. (INVT) is an intellectual property (IP) licensing partner specializing in IP value creation. Led by industry veteran Joe Beyers, former head of global licensing for Hewlett-Packard, Inventergy identifies, acquires and licenses patented technologies to help market-leading technology companies monetize and achieve more value from their innovations.
With more than 100 years of combined experience and track record of handling more than $15 billion in IP and technology transactions, Inventergy’s team of professionals handle every aspect of the IP business, from valuation and branding through legal analysis, decision making and patent sales.
Inventergy partners with world-class, market-significant companies who may lack internal manpower, budget or other resources necessary to realize appropriate return-on-investment. Through collaborative, business-centered, and forward-thinking strategies, Inventergy is able to create portfolios with significant market potential and optimize the innovator’s overall return-on-investment.
The company has established a network of key industry relationships to complement its solid licensing model and growing portfolio of assets, which currently stands at more than 760 global patent assets. Inventergy pursues maturing telecommunications technologies already adopted in the marketplace and earning accretive value. Disclaimer
Inventergy Global, Inc. Company Blog
Inventergy Global, Inc. News:
Inventergy Issued New Patent for Data Transmission Enhancement
Inventergy Strengthens Its Financial Management and Investor Relations (IR) Processes
Inventergy Announces $2.15 Million Common Stock Financing to Accelerate Licensing Operations
Galenfeha, Inc. (GLFH)
The QualityStocks Daily Newsletter would like to spotlight Galenfeha, Inc. (GLFH). Today, Galenfeha, Inc. closed trading at $0.38, up 2.70%, on 3,500 volume with 3 trades. The stock’s average daily volume over the past 60 days is 30,916, and its 52-week low/high is $0.1011/$4.00.
Galenfeha, Inc. (GLFH) is an engineering, product development, and manufacturing company that provides innovative solutions for oil and natural gas production, as well as stored energy products across a number of different industries. The company provides these products and services through its stored energy and oil & gas division.
Through its stored energy division, Galenfeha offers one of the most powerful, environmentally friendly battery systems in the market. The batteries have onboard computers, are inherently safe, internally temperature regulated, have optional GPS monitoring capabilities, offer significant weight reduction of up to 50%, and are engineered specifically for each type of application. Features include 100% “green” chemistry, RoHS compliancy, and active short circuit protection control.
Through its oil and gas division, the company offers chemical injection pumps that merge the perceived benefits of a hybrid, electric over pneumatic system. Galenfeha management believes the combination of the two parameter control systems represents a measurable shift in efficiency, reliability, cost management, and profitability to individual well locations as well as entire production fields. The combined technologies have demonstrated increased chemical injection accuracy, reducing chemical contamination in the production process while controlling cost and waste.
The company’s unwavering dedication is to continuously develop products that perform better than conventional solutions while also reducing environmental impact. Leveraging the management team’s wealth of resources and relationships, Galenfeha is well positioned for continued growth as the company aims to expand in both the stored energy and oil & gas industries. Disclaimer
Galenfeha, Inc. Company Blog
Galenfeha, Inc. News:
GALENFEHA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Galenfeha, Inc. Completes Field Testing, Begins Production and Shipping of New Battery System
Galenfeha Helping American Frackers Beat OPEC
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.0583, up 2.28%, on 289,736 volume with 35 trades. The stock’s average daily volume over the past 60 days is 859,082, and its 52-week low/high is $0.045/$0.185.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
International Stem Cell Corporation Presents Data From Parkinson's Disease Program at AAN Annual Meeting
International Stem Cell Corporation Demonstrates Reversal of Neurological Stroke Symptoms Using Neural Stem Cells
One World Holdings, Inc. (OWOO)
The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0032, even for the day, on 1.898,328 volume with 31 trades. The stock’s average daily volume over the past 60 days is 4,349,913, and its 52-week low/high is $0.0008/$0.09.
One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.
In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.
The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.
Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer
One World Holdings, Inc. Company Blog
One World Holdings, Inc. News:
One World Holdings Announces Yearly Revenue Increase of 532%
One World Holdings Raises Capital to Fund National Expansion and Convertible Note Elimination
The One World Doll Project to Announce National Retail Store Roll Out of the Prettie Girls! Dolls On April 6 Conference Call
Pure Hospitality Solutions, Inc. (PNOW)
The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.003, even for the day, on 390,600 volume with 3 trades. The stock’s average daily volume over the past 60 days is 751,129, and its 52-week low/high is $0.0013/$0.6471.
Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.
The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.
Operating a successful bi-lateral business model, Pure has four objectives:
1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;
2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;
3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,
4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.
The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.
Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer
Pure Hospitality Solutions, Inc. Company Blog
Pure Hospitality Solutions, Inc. News:
National Tourism Center Of Costa Rica Gives Pure Opportunity
Pure's Oveedia Signs First Property
Pure Retains Softon to Accelerate Photo Share Software
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.10, even for the day. The stock’s average daily volume over the past 60 days is 4,498, and its 52-week low/high is $0.015/$0.18.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulted on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
LOANS4LESS.COM Enters into an Acquisition Agreement with 321LEND
Loans4Less.com, Inc. Enters into an Investment Banking Agreement with WestPark Capital, Inc. and Seeks Bank Strategic Partner for National Mortgage Broker Origination and Brand Exposure Opportunity
Loans4Less.com Seeks a Merger, Joint Venture Partner and/or Investor for National Loan Origination and Brand Exposure Opportunity
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.1601, off by 0.12%, on 31,659 volume with 10 trades. The stock’s average daily volume over the past 60 days is 33,653, and its 52-week low/high is $0.13/$0.95.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
- Cleartronic, Inc. (CLRI) Adds Shareholder Value With Cancellation of Two Billion Shares of Common Stock Held by CEO
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
- Falcon Crest Energy (FCEN) Searching for Opportunities Outside Oil and Gas Sector
- Galenfeha, Inc. (GLFH) Completes Field Testing, Begins Production and Shipping of New Battery System
- International Stem Cell Corp. (ISCO) Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
- Inventergy Global, Inc. (INVT) Strengthens Its Financial Management and Investor Relations (IR) Processes
- Loans4Less.com Inc. (LFLS) Enters into an Acquisition Agreement with 321LEND
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International
- One World Holdings, Inc. (OWOO) Raises Capital to Fund National Expansion and Convertible Note Elimination
- Pure Hospitality Solutions, Inc. (PNOW) National Tourism Center Of Costa Rica Gives Pure Opportunity
- Save The World Air, Inc. (ZERO) Reports 2014 Year-End Financial Results and Provides Operational Update
- Sibling Group Holdings, Inc. (SIBE) Urban Planet Mobile Deepens Strategic Partnership With Imagine Easy Solutions and EasyBib; UPMs Writing Planet Essay Scoring Solution to Be Offered Across All Imagine Easy Citation Websites Worldwide
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors
- Zenosense, Inc. (ZENO) Hospital Collaboration - 400 Person Lung Cancer Detection Trial